Quart Barry D 4

What Happened Barry D. Quart, a director of Kiniksa Pharmaceuticals International (KNSA), exercised stock options to acquire a total of 2,800 shares (110 on Feb 10 and 2,690 on Feb 12) at $15.47 per share (total cost $43,316) and then sold those same 2,800 shares in open‑market transactions at $45.00 per share for total gross proceeds of $126,000. The exercises and immediate sales function like a cashless exercise: options were converted into shares and the shares were sold. These transactions were effected pursuant to a 10b5‑1 trading plan.

Key Details

• Transaction types: Option exercises (Form 4 code M) and open‑market sales (S). Two exercise/sale events: 2026-02-10 and 2026-02-12.
• Quantities & prices: Acquired 110 shares @ $15.47 (2/10) and 2,690 shares @ $15.47 (2/12); sold 110 shares @ $45.00 (2/10) and 2,690 shares @ $45.00 (2/12).
• Totals: 2,800 shares acquired for $43,316 and sold for $126,000 (gross proceeds); net proceeds ≈ $82,684 before taxes/fees.
• Footnotes: Transaction effected under a 10b5‑1 plan executed Sept 11, 2025 (F1). The options exercised were fully vested and exercisable (F2).
• Shares owned after transaction: Not specified in this filing.
• Filing timeliness: Report filed 2026-02-12 covering transactions dated 2026-02-10 and 2026-02-12; no late‑filing indication in this report.

Context

• This was an option exercise followed by immediate sales (a common cashless exercise pattern). The 10b5‑1 plan indicates the sales were pre‑arranged under a trading plan, which is typically used to avoid timing concerns.
• The filing is factual record of the exercise and sale; it does not state the insider’s motivation.